In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.62 a new company low.

Within Major Pharmaceutical Preparations industry 383 other companies have achieved higher Quick Ratio than Enanta Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 746 to 2426.

Explain Quick Ratio?
How much Cash & cash equivalents ENTA�s has?
What are ENTA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ENTA/financial-strength

https://api.csimarket.com/api/v1/companies/ENTA/fundamentals

https://api.csimarket.com/api/v1/companies/ENTA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ENTA Quick Ratio	(Jun 30 2026) Q3	(Mar 31 2026) Q2	(Dec 31 2025) Q1	(Sep 30 2025) Q4	(Jun 30 2025) Q3
Y / Y Current Liabilities Change	21.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-83.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.62	Subscribe	Subscribe	Subscribe	Subscribe
ENTA's Total Ranking	# 2426	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	16.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-79.59 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 384
Healthcare Sector	# 712
Overall Market	# 2426

Quick Ratio Statistics
High	Average	Low
72.93	17.94	0.62
(Sep 30 2015)		(Jun 30 2026)

Financial Statements
Enanta Pharmaceuticals Inc's Current Liabilities	$ 54 Millions	Visit ENTA's Balance sheet
Enanta Pharmaceuticals Inc's Cash & cash equivalent	$ 33 Millions	Visit ENTA's Balance sheet
Source of ENTA's Sales		Visit ENTA's Sales by Geography

Cumulative Enanta Pharmaceuticals Inc's Quick Ratio

ENTA's Quick Ratio for the trailling 12 Months

ENTA Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-1.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-9.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1550	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.22 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-18.02 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ENTA Financial Strength Comparisons >> Go to Compare ENTA Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $54.17 millions, cumulative Quick Ratio decreased to 4 above the ENTA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Enanta Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2716 to 4015.

Explain Quick Ratio?
How much Cash & cash equivalents ENTA�s has?
What are ENTA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 901
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.55	2.66	0.67
(Dec 31 2013)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Nuvectis Pharma inc	1.67	$ 22.160 Millions	$ 13.294 Millions
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions
Fibrobiologics Inc	1.59	$ 3.515 Millions	$ 2.213 Millions
Sarepta Therapeutics Inc	1.57	$ 788.489 Millions	$ 502.908 Millions
Revium Rx.	1.55	$ 1.506 Millions	$ 0.971 Millions
Connect Biopharma Holdings Limited	1.53	$ 27.015 Millions	$ 17.701 Millions
Liquidia Corporation	1.50	$ 284.181 Millions	$ 189.298 Millions
Greenwich Lifesciences Inc	1.50	$ 8.876 Millions	$ 5.923 Millions
Arcutis Biotherapeutics Inc	1.49	$ 238.552 Millions	$ 160.340 Millions
Mirum Pharmaceuticals Inc	1.48	$ 330.728 Millions	$ 222.788 Millions
Regeneron Pharmaceuticals Inc	1.45	$ 7,994.600 Millions	$ 5,530.600 Millions
Imunon Inc	1.44	$ 6.900 Millions	$ 4.779 Millions
Zai Lab Limited	1.44	$ 617.522 Millions	$ 428.584 Millions
Mannkind Corporation	1.44	$ 205.271 Millions	$ 142.898 Millions
Kyntra Bio Inc	1.41	$ 50.644 Millions	$ 36.040 Millions
Medicus Pharma Ltd	1.40	$ 15.174 Millions	$ 10.841 Millions
Aurinia Pharmaceuticals Inc	1.39	$ 179.732 Millions	$ 129.084 Millions
Omeros Corporation	1.39	$ 131.953 Millions	$ 94.963 Millions
Avenue Therapeutics Inc	1.38	$ 1.942 Millions	$ 1.407 Millions
Royalty Pharma Plc	1.33	$ 836.986 Millions	$ 630.928 Millions
Cormedix Inc	1.31	$ 256.692 Millions	$ 196.535 Millions
Transcode Therapeutics Inc	1.30	$ 8.383 Millions	$ 6.430 Millions
Elite Pharmaceuticals Inc	1.28	$ 39.032 Millions	$ 30.442 Millions
Ani Pharmaceuticals Inc	1.27	$ 360.212 Millions	$ 283.655 Millions
Pmgc Holdings Inc	1.25	$ 19.126 Millions	$ 15.329 Millions
Petros Pharmaceuticals inc	1.23	$ 3.489 Millions	$ 2.845 Millions
Nature s Sunshine Products inc	1.20	$ 82.503 Millions	$ 68.745 Millions
Phathom Pharmaceuticals Inc	1.19	$ 182.478 Millions	$ 153.777 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.